The Open Targets Blog

JANUARY 30, 2025

  “Sam has an exceptional talent in software engineering, and his contributions reflect a deep understanding of both the technical and biological aspects required for bioinformatics tool development,” says Laura Luebbert, now a postdoctoral fellow in the Sabeti lab at the Broad Institute of MIT and Harvard and Harvard University.

Bioinformatics 76

Bioinformatics Immune Response RNA Packaging 76

Drug Target Review

AUGUST 11, 2023

1 The study reveals a novel bioinformatic approach and tool that holds the potential to empower researchers in designing vaccines capable of inducing a stronger immune response. By selecting specific segments of proteins that elicit robust immune reactions, these vaccines could offer enhanced protection against diseases.

Vaccine 98

Vaccine Immune Response Bioinformatics Virus 98

Drug Target Review

DECEMBER 13, 2023

Combinatorial analytics approaches identify combinations of features that together are associated with the disease phenotype in patient sub-groups, capturing the non-linear effects of interactions between multiple genes. The combinatorial approach is considerably more sensitive than GWAS and requires much smaller patient populations.

Bioinformatics 145

Bioinformatics Disease Regulations Immune Response 145

Drug Target Review

DECEMBER 28, 2023

These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response. Recent advances in bioinformatics show clonal neoantigens are the best targets for immunotherapy, as I will elucidate below. Neoantigens are recognised as non-self and trigger an immune response.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

Drug Target Review

JANUARY 15, 2024

Cancer is a disease driven by variable genetic mutations. Our innate immune system evolved to clear genetically diverse pathogens and limit host toxicity, raising the possibility that it can produce similar effects in cancer. The preclinical results demonstrated significant immune responses and tumour regression.

Treatment 105

Treatment Immune Response Therapies Clinical Trials 105

PLOS: DNA Science

MAY 16, 2024

These factors are converging to enable both identification of novel infectious diseases as well as microbial resistance, before these threats can impact public health, write a team from the European Society for Clinical Microbiology and Infectious Diseases in Frontiers in Science. COVID clearly caught us off guard.

Virus 98

Virus DNA RNA Vaccine 98

Codon

AUGUST 27, 2024

Doctors in training are told that when they hear hoofbeats, they should think horses, not zebras; rare diseases are the exception, not the rule. Sometimes, though, novel diseases do emerge, and as COVID-19 demonstrated, they can surprise us. This is the third essay of four in our pandemic mini-issue.

DNA 97

DNA Laboratories Hospitals Virus 97